Astellas Pharma Inc. Newsletter
-
Astellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call Transcript
26 Apr 2025 23:54 GMT
Astellas Pharma Inc. (OTCPK:ALPMF) Q4 2024 … Financial Results Announcement Meeting by Astellas Pharma Inc. out of your very … factors. They contain information on pharmaceuticals, including compounds under development, but …
-
Global Pharma Companies Rush to Invest in U.S., as Trump Administration Examines Tariff on Drug Imports
27 Apr 2025 11:09 GMT
… soon impose new tariffs on drug imports. Pharma companies are trying to … not affect pharmaceuticals, his administration has already begun investigating drug imports, looking … ,” said Naoki Okamura, president of Astellas Pharma Inc., at a press conference …
-
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
25 Apr 2025 11:10 GMT
… by other companies.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a … Japan, Ironwood's partner, Astellas, markets linaclotide under the brand … product candidates, including abbreviated new drug application litigation; the risk …
-
Drug Targets Identified for Pancreatic Cancer
24 Apr 2025 21:56 GMT
… Oncology, RAPTTA Therapeutics, and Ascentage Pharmaceuticals. Chinnaiyan, Qiao, Lyssiotis, Cheng, Bao … years, Lyssiotis has consulted for Astellas Pharmaceuticals, Odyssey Therapeutics, Third Rock Ventures …
-
Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea
24 Apr 2025 05:15 GMT
… developing and commercializing innovative drugs to meet the needs of … or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its …
PMDA List of Approved Drugs April 2022 to March 2023 … : https://www.astellas.us/docs/cresemba …
-
Starke Verkäufe von Cresemba® (Isavuconazol) in Japan lösen zweite Umsatzmeilensteinzahlung von Asahi Kasei Pharma an Basilea aus
24 Apr 2025 05:15 GMT
… » oder ähnliche Ausdrücke betreffend Basilea Pharmaceutica AG, Allschwil und ihrer Geschäftsaktivitäten … -Dollar.
PMDA List of Approved Drugs April 2022 to March 2023 … -Verschreibungsinformationen: https://www.astellas.us/docs/cresemba …
-
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
22 Apr 2025 20:24 GMT
… head of research and drug development at Ironwood Pharmaceuticals. “Given our ongoing … ’s, Hartford, CT.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a … Japan, Ironwood's partner, Astellas, markets linaclotide under the brand …
-
Astellas Pharma';s monoclonal antibody treatment approved in Singapore for GEJ cancer
12 Apr 2025 18:30 GMT
…
Singapore HSA has approved, Astellas Pharma Inc. VYLOYTM (zolbetuximab), an … said Aycin Oguz, General Manager, Astellas Pharma Singapore and Malaysia.
“This … Rebecca Chng, Head, Medical Affairs, Astellas Pharma Singapore and Malaysia. “In Singapore …
-
Astellas Pharma';s monoclonal antibody treatment approved in Singapore for Gastric and GEJ cancer
12 Apr 2025 18:30 GMT
… .
Singapore HSA has approved, Astellas Pharma Inc. VYLOY™ (zolbetuximab), an … said Aycin Oguz, General Manager, Astellas Pharma Singapore and Malaysia.
“This approval … Rebecca Chng, Head, Medical Affairs, Astellas Pharma Singapore and Malaysia. “In Singapore …
-
Royalty Pharma Declares Second Quarter 2025 Dividend
21 Apr 2025 20:15 GMT
… companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio … industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical … Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis …
About
© 1995-2025